Humoral and Cell Mediated Immune Response After Immunization with Varicella Vaccine (Oka/LG)

PURPOSE: We evaluated the humoral and cellular immune response to varicella-zoster virus after vaccination with varicella vaccine (Oka/LG strain). METHODS: The seroprevalence rate of fluorescent antibody to membrane antigen (FAMA) was evaluated among 178 children and 15 adults. After vaccination, seroconversion rate of FAMA, varicella-zoster virus (VZV) specific IgG and cell mediated immune response to glycoprotein I was performed. RESULTS: The seropositive rate of FAMA against VZV in healthy children ages 3 to 6 was 43.1%. A past history of chickenpox illness was confirmed in 15.2% of children who had positive response in FAMA assay in 90.9%. 34.5% of those without a past history of chickenpox had antibodis. The seropositive rate in children vaccinated with varicella vaccine in the past was found to be 46.3% in questionnaire and 44.4% in immunization schedule, lower than that of other studies (greater than 90%). The seroconversion rates in children vaccinated with the Oka/LG were 97.1% with 2,500pfu and 100.0% with 5,000pfu. Antibodies appearing after the Oka/LG vaccination were found to have glycoprotein I zone confirmed by western blotting. The rate of cell mediated immune response was 88.2% in children and 100.0% in adults. CONCLUSION: Further investigation about the effect of the various varicella vaccines used in Korea and about the cause of their immunzation failure after vaccination is needed.

Neutralizing Antibody Response To Two Doses Of Formalin Inactivated Mouse Brain-Derived Hantaan Virus Vaccine(HantavaxR) In Healthy Adults / 감염

BACKGROUND: Hemorrhagic fever with renal syndrome is a serious health problem in Korea. Formalin inactivated mouse brain-derived Hantaan virus vaccine (HantavaxR) has been available since 1990 and recom-mended in national immunization programs for children and adults by the health authority. However, Hantavax has not been evaluated for efficacy in a randomized, placebo-controlled clinical trial and data on neutralizing antibody responses in human trials are limited. To investigate humoral immune responses to Hantavax, we studied volunteers immunized according to the recom-mended two dose schedule. METHODS: With informed consent, 30 healthy adults were immunized with two doses of Hantavax (Lot No. 6001, 2360002) 0.5ml given intramuscularly on deltoid muscle 4 weeks apart. The monovalent vaccine, pro-duced from the ROK 84-105 strain, is inactivated with 0.05% formalin and has an ELISA antigen titer of 4096. Sera were collected before vaccination and 4 weeks after each dose for a total of 90 serum samples from 30 vaccinees. Neutralizing antibodies were measured at Unit-ed States Army Medical Research Institute of Infectious Disease (Ft. Detrick, MD) in plaque reduction neutrali-zation tests. Antibody titers were expressed as the highest serum dilution that reduced the standard viral dose (45 ~ 58 plaque forming units of Hantaan virus strain 76-118 by 50 percent. Serum binding antibodies also were mea-sured in a high density particle agglutination test (Hanta-dia R) at Yonsei University. RESULTS: Neutralizing antibodies were detected in only 5 of 30 vaccinees given two doses of Hantavax, yielding seroconversion rate of 16.7%. The endpoint titers of reactive sera were 1:320, 1:10, 1:10, 1:10, and 1:40 respectively. The seroconversion rate measured by high density particle agglutination test was 80.0% (24/30). CONCLUSION: These results indicated that the poor neutralizing antibody response observed in this study suggests that further evaluations of the protective effi-cacy of inactivated mouse brain-derived Hantaan virus vaccine against HFRS.

A clinicopathologic study of lupus nephritis in children / 대한신장학회잡지

No abstract available.

Urinary calcium excretion of Korean children / 대한신장학회잡지

No abstract available.

A clinical study of testicular relapse in childhood acute lymphocytic leukemia

From January 1984 to June 1991, we studied testicular relapsed patients among 105 cases of acute lymphocytic leukemia in children who were admitted to the Department of Pediatrics and Yonsei Cancer Center, Yonsei University Severance Hospital. The results were as follows: 1) 15 out of 105 (14.4%) cases of acute lymphocytic leukemia were diagnosed as testicular relapse. According to the prevalence by the age groups, there were no patient under 2 years old, 14 out of 73 (19.4%) in 2~9 years old and 1 out of 26 (3.8%) over 10 years old groups. 2) At initial diagnosis of acute lymphocytic leukemia there were significant correlation between testicular relapse and initial lymphadenopathy (p=0.09), but not with WBC count, hemoglobin level, platelet count, hepatomegaly and splenomegaly. 3) Mean duration to testicular relapse from initial diagnosis of acute lymphocytic leukemia was 3.1+/-1.7 years. 4) Among 15 patients, 7 cases combined with bone marrow or central nervous system relapse. Their survival rate was lower than isolated testicular relapse groups. 5) The 5 years survival rate of testicular relapsed patients was 67% after the combinations of chemotherapy, radiotherapy and orchiectomy.

Hodgkin's disease in a child with acute lymphoblastic leukemia

Hodgkin's disease, manifested as a second malignant neoplasm in acute lymphoblastic leukemia, rarely occurs, with seventeen cases reported including this cases. We presented the clinical and pathological features of a nine-year-old male child with acute lymphoblastic leukemia in remission. He had cervical lymph node involvement 22 months after the diagnosis of leukemia as an initial presentation of Hodgkin's disease of mixed cellularity. A brief review of related literatures was also done.